<DOC>
	<DOC>NCT01578070</DOC>
	<brief_summary>The purpose of this study is to show that ViscoGel速 is safe when administrated alone and as an adjuvant together with Act-HIB速 vaccine in healthy volunteers and to evaluate the quantitative and qualitative effect on the immune response.</brief_summary>
	<brief_title>Single-center Study Evaluating the Safety and Efficacy of Viscogel速 as Adjuvant in Act-HIB速 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>Subjects who have signed a written informed consent consistent with ICH GCP guidelines and local legislations prior to participation in the trial. Subjects who are healthy and with no relevant medical history as determined by the investigator. Subject that has not previously been known to be infected with or vaccinated against HIB, or exposed to patients diseased with HIB within a 4 months period prior to screening. Male and nonlactating female subjects 2250 years of age. Two negative pregnancy tests if female (at screening and day 0) Contraceptive use if female i.e. using a highly effective contraceptive method (implants, injectables, combined oral contraceptives, intrauterine devices [including hormonal intrauterine devices], sexual abstinence or vasectomised partner) for at least one month before dosing and willing to use it for at least one month after dosing. Able to read and write Swedish. Known allergy to any component in ActHIB, or who have had a serious reaction after previous administration of a vaccine. Fever or acute disease including fever. Receipt of immunoglobulins or blood products within three months prior to screening. Donation of blood or suffered of blood loss of 450 ml within 3 months (4 months if female) prior to screening. Donation of plasma within 14 days prior to screening. Participation in other clinical study within 3 months prior to screening or previously dosed in this study. Known or suspected immunodeficiency. Vaccination received within a 2 months period prior to screening. Any condition where regular use of inhaled, topical or oral corticosteroid is used. Any condition where use of immunosuppressant is needed, e.g rheumatoid arthitis, cancer, transplantation, or treatment with immunomodulators, e.g. antiTNF alpha, methotrexte, thioguanine, cyclophosphamide, cyclosporine, tacrolimus. Smoker or user of other nicotine products at the discretion of the investigator. Drug or alcohol abuse or history of drug or alcohol abuse in the past 5 years prior to screening. Any medical condition or other circumstances that in the opinion of the investigator might interfere with the study. Abnormal clinically significant laboratory values, ECG findings, vital signs or physical examination findings as judged by the investigator. Inability to adhere to the protocol including plans to move from the area. Use of any prohibited medication (including dietary supplements and herbal medication) within 2 weeks or 7 halflives (whichever is longer) of day 0. Any positive result at screening for serum hepatitis B surface antigen (HBsAG), hepatitis C antibody (antiHCV) or human immunodeficiency virus (HIV) I and II.</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Other and Unspecified Vaccines and Biological Substances Causing Adverse Effects in Therapeutic Use</keyword>
</DOC>